Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Trevena (NASDAQ: TRVN) shares are trading higher on Friday after Cantor Fitzgerald initiated coverage on the company's stock with an Overweight rating and announced a $5 price target.

Why Trevena's Stock Is Trading Higher Today

--     Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

Trevena Announces Publications of OLINVYK™ Respiratory Safety Analyses vs. IV Morphine

Trevena (NASDAQ: TRVN) shares traded higher on Monday after the company announced the initiation of its TRV027 study in COVID-19 patients in collaboration with Imperial College London.

Why Trevena's Stock Is Moving Today

--   TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London

--   $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection

Trevena Announces Receipt of Milestone Payment Under Partnership in China With Jiangsu Nhwa Pharmaceutical Co.

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

Implied Volatility Surging for Trevena (TRVN) Stock Options

CHESTERBROOK, Pa., Aug.  14, 2020  (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020.

Trevena to Present at the Virtual JMP Securities CNS Forum

The biopharmaceutical company announced the pricing of a public offering of common stock.

Why Trevena Stock Is Plunging Today

CHESTERBROOK, Pa., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today the pricing of its previously announced underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $2.30 per share. Trevena has also granted the underwriters a 30-day option to purchase up to 3,260,869 additional shares of common stock, at the public offering price, less underwriting discounts and commissions. The gross proceeds of the offering are expected to be approximately $50 million, before deducting the underwriting discounts and commissions and other offering expenses. The closing of the offering is expected to occur on or about August 14, 2020, subject to the satisfaction of customary closing conditions.

Trevena Announces Pricing of $50 Million Public Offering of Common Stock

CHESTERBROOK, Pa., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (“CNS”) disorders, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Trevena intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Trevena Announces Proposed Public Offering of Common Stock

The biotech's innovative painkiller is the first new drug in its class in decades.

Why Trevena Stock Surged Today

OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic

Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection

Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Trevena (TRVN) Looks Good: Stock Adds 8.8% in Session

Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain

Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.

--     TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS

Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

Is  (TRVN) Outperforming Other Medical Stocks This Year?

Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2020 Results - Earnings Call Transcript

Has Trevena, Inc.
(TRVN) Outpaced Other Medical Stocks This Year?

Trevena has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Trevena Enters Oversold Territory

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q4 2019 Results - Earnings Call Transcript

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

FDA considers NDA resubmission a complete Class 2 response

Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine

CHESTERBROOK, Pa., Feb.  13, 2020  (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the appointment of Scott Applebaum as Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs. Mr. Applebaum comes to the Company with over 20 years of experience in a variety of senior leadership roles at both large and small companies at various stages of development and commercialization in the biopharmaceuticals sector.

Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

News for Trevena Stock (TRVN)